New combo therapy aims to keep esophageal cancer from coming back
NCT ID NCT03322267
First seen Mar 07, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy after surgery could help prevent esophageal cancer from returning in patients at high risk of recurrence. 26 adults with locally advanced esophageal squamous cell carcinoma who had already received chemoradiotherapy before surgery took part. The goal was to see if this approach improved the chance of being cancer-free one year later compared to historical data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.